– EMA CLAIMS MAJOR GROWTH IN DEVELOPMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS
January 7th, 2015
THE CHAIR of the European Medicine Agency’s (EMA) committee of advanced therapies (CAT) has claimed a sharp increase in the development of such sophisticated medicines. Paula Salmikangas told a European Biopharmaceutical Enterprises (EBE1), EMA and Italian government-run workshop, in London, there had been “major growth” in advanced medicines development. EMA advanced therapy medicinal product (ATMP) classifications now numbered 117; there had been 200 cases of requested scientific advice; and 40 sets of advice on ATMP paediatric investigation plans ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.